游离前列腺特异性抗原联合癌胚抗原对前列腺癌的早期诊断价值  

Free prostate specific antigen combined with carcinoembryonic antigen for early diagnosis of prostate cancer

作　　者：陈妹[1] 陈玲[1] 曹明杰[1] Mei Chen;Ling Chen;Ming-jie Cao(Department of Clinical Laboratory,The First People’s Hospital of Chuzhou,Chuzhou,Anhui 239000,China)

机构地区：[1]滁州市第一人民医院检验科,安徽滁州239000

出　　处：《中国现代医学杂志》2020年第20期82-86,共5页China Journal of Modern Medicine

摘　　要：目的分析游离前列腺特异性抗原(fPSA)联合癌胚抗原(CEA)对前列腺癌的早期诊断价值。方法选取2017年1月-2019年12月在滁州市第一人民医院就诊的256例疑似前列腺癌患者作为研究对象。血清总前列腺特异抗原(tPSA)水平介于4.0~20.0μg/L,根据血清tPSA水平分为tPSA 4.0~10.0μg/L组180例和tPSA 10.1~20.0μg/L组76例。比较两组前列腺癌与非前列腺癌患者血清fPSA、CEA、游离与总前列腺特异性抗原比值(f/tPSA)、前列腺健康指数(PHI)。进行Pearson相关性分析和线性回归性分析,使用受试者工作特征曲线下面积(AUC)评价fPSA联合CEA对前列腺癌的诊断效能。结果 tPSA 4.0~10.0μg/L组前列腺癌与非前列腺癌患者血清fPSA、CEA水平比较,差异有统计学意义(P<0.05);而年龄、血清tPSA水平、f/t PSA及PHI比较,差异无统计学意义(P>0.05)。tPSA 10.1~20.0μg/L组前列腺癌与非前列腺癌患者血清fPSA、CEA及PHI比较,差异有统计学意义(P<0.05);而年龄、血清tPSA水平及f/t PSA比较,差异无统计学意义(P>0.05)。Pearson相关性分析显示,前列腺癌患者血清fPSA、CEA水平与PHI呈正相关(r=0.348和0.392,P<0.05)。线性回归分析显示,血清fPSA、CEA水平是PHI水平的影响因素(b=0.046和0.449,P<0.05)。ROC曲线结果显示,FPSA联合CEA诊断前列腺癌的AUC为0.921,大于fPSA的0.672和CEA的0.703(P<0.05)。结论 fPSA和CEA是早期诊断前列腺癌的重要线索,两者联合诊断血清tPSA低水平升高前列腺癌的效能较好,可能成为更好的前列腺癌早期诊断的新途径。Objective To analyze the early diagnostic value of free prostate specific antigen (fPSA) combined with carcinoembryonic antigen (CEA) for prostate cancer.Methods A total of 256 patients with suspected prostate cancer who were admitted to our hospital from January 2017 to December 2019 were selected as the research subjects.The serum total prostate specific antigen (tPSA) level of the included participants was between 4.0 and 20.0 μg/L.According to serum tPSA levels,patients were divided into tPSA 4.0~10.0 μg/L group (180 patients) and tPSA 10.1~20.0 μg/L group (76 patients).The serum fPSA,CEA levels and ratio of free to total prostate-specific antigen (f/t PSA),and prostate health index (PHI) were compared between the groups.The area under the receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of fPSA combined with CEA for prostate cancer.Results In the tPSA 4.0~10.0 μg/L group,the serum fPSA and CEA levels of prostate cancer patients and non-prostate cancer patients were significantly different (P<0.05).There was no significant difference in the age,serum tPSA level,f/t PSA,and PHI between prostate cancer patients and non-prostate cancer patients (P>0.05).In the tPSA 10.1~20.0μg/L group,the serum fPSA,CEA,and PHI of prostate cancer patients were significantly different between prostate cancer patients and non-prostate cancer patients (P<0.05),while there was no statistically significant difference in the age,serum tPSA level,and f/t PSA between patients with prostate cancer and those without prostate cancer (P>0.05).According to Pearson correlation analysis,serum fPSA (r=0.348) and CEA levels (r=0.392) of prostate cancer patients were positively correlated with PHI (P<0.05).The linear regression analysis showed serum fPSA levels (b=0.046) and CEA levels (b=0.449) were both influencing factors of PHI level (P<0.05).The ROC curve analysis showed that the AUC of fPSA combined with CEA for the diagnosis of prostate cancer was 0.921,which was significantly greater than 0.6

关 键 词：前列腺肿瘤 癌胚抗原 早期诊断 

分 类 号：R736.1[医药卫生—肿瘤]